Herpes zoster neuralgia,Postherpetic neuralgia
Conditions
Interventions
Ideal group (retrospective cohort):None
Non-ideal group (retrospective cohort):None
Ideal group (prospective cohort):None
Non-ideal group (prospective cohort):None
Sponsors
The Second Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.retrospective study:; 1.Age >= 18 years old; 2.Clinical diagnosis of postherpetic neuralgia (PHN): pain persisting for >= 1 month after rash resolution; 3.Receiving st-SCS therapy (stimulation duration: 7–14 days); 4.Preoperative high-quality MRI available for DRG typing (3D-T2-SPACE or heavily T2-weighted CISS sequence, slice thickness =18 years, =1 month after rash healing Pain; 3.VAS score >=5 (moderate to severe pain); 4.Poor response to drug therapy (at least two types of medication with standard treatment for over 4 weeks); 5.Voluntarily accept st-SCS treatment and sign informed consent; 6.Preoperative high-quality MRI (3D-T2-SPACE or heavy T2 CISS sequence) available for DRG classification;
Exclusion criteria
Exclusion criteria: Retrospective study: 1. Previous history of spinal surgery; 2. Comorbid with other chronic pain disorders (such as fibromyalgia, rheumatoid arthritis); 3. Inadequate MRI quality (motion artifacts, slice thickness > 1.0mm, inability to identify DRG); 4. Severe complications during st-SCS treatment (infection, hematoma, etc.) resulting in premature termination; 5. Missing key data (absence of primary outcome indicators); Prospective study: 1. Previous history of spinal surgery; 2. Comorbid with other chronic pain disorders (such as fibromyalgia, complex regional pain syndrome); 3. Severe mental illness or cognitive impairment, unable to cooperate with assessment; 4. Coagulation dysfunction or inability to discontinue anticoagulant therapy; 5. Local or systemic active infection; 6. Pregnancy or lactation; 7. Implantation of cardiac pacemaker or other MRI contraindications;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At 1 month postoperatively, the resting VAS score decreased by =50% compared with the preoperative baseline (T0).;Difference in central sensitization between preoperative and 1-month postoperative;DRG (dorsal root ganglion) classification; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug dosage reduction;Sleep Disturbance Score;Incidence rate of adverse events; | — |
Countries
China
Contacts
Public ContactMo Hongxia
The Second Affiliated Hospital of Guangxi Medical University
Outcome results
None listed